CACNA1A and fragile X-associated tremor/ataxia syndrome: Unfortunately, individuals with pre-symptomatic and early stages of disease, who represent the ideal target for upcoming preventive trials, were underrepresented in the published literature: studies involving pre-symptomatic subjects exist for SCA2, SCA3, SCA6, NPC, and FXTAS only.